11C-PIB PET allows to simultaneously map demyelination and remyelination in vivo and to generate quantitative maps of brain perfusion. In 15 relapsing-remitting MS patients, 11C-PIB PET and 3T MRI were performed at baseline and 2-4 months later. At baseline, 904 lesions were identified on T2-weighted scans. Gadolinium-enhancing lesions were excluded. Successful repair of lesions was defined as remyelination of ≥50% of demyelinated voxels, and demyelination over the follow-up in <25% of voxels that were classified as normally myelinated at study entry.
There was lower perfusion in white matter lesions than in normal-appearing white matter (0.43 vs 0.49; P<0.001). However, single-lesion R1 values were very heterogeneous (range 0.08-2.5). In single lesions, higher baseline perfusion was associated with more extensive remyelination (β=0.32; P<0.001) and reduced demyelination (β=-0.28; P<0.001). Lesion-specific perfusion at baseline was an independent predictor of successful myelin repair (OR 8.4; P<0.001).
- Colombi A, et al. Lesion-specific perfusion levels affect myelin loss and repair in multiple sclerosis: a positron emission tomography study. MSVirtual 2020, Abstract PS11.03.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Management of progressive MS with approved DMT Next Article
Grey matter network measures predict disability and cognition »
« Management of progressive MS with approved DMT Next Article
Grey matter network measures predict disability and cognition »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

August 27, 2019
Prognostic blood and MRI biomarkers
August 27, 2019
Autologous haematopoietic stem cell transplantation
September 10, 2020
High NEDA rates after 2 years of ocrelizumab
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy